Meng-Yao Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meng-Yao Xiong has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Baoxue Yang
Department of Pharmacology, School of Basic Medical Sciences Peking University Beijing China
1 shared publication Bo-Yang Cai
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China
1 shared publication- Chang-Xiu Qu
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China
1 shared publication - Chao Zhang
Institute of Brain Science and Brain-inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
1 shared publication - Chenyang Xue
Department of Immunology and Microbiology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China
1 shared publication - Fan Yang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Shandong University, Jinan, China
1 shared publication
Latest Publications
- Open Access
- 21 July 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (30)
Single hormone or synthetic agonist induces Gs/Gicoupling selectivity of EP receptors via distinct binding modes and propagating paths
To accomplish concerted physiological reactions, nature has diversified functions of a single hormone at at least two primary levels: 1) Different receptors recognize the same hormone, and 2) different cellular effectors couple to the same hormone–receptor pair [R.P. Xiao,Sci STKE2001, re15 (2001); L. Hein, J. D. Altman, B.K. Kobilka,Nature402, 181–184 (1999); Y. Daaka, L. M. Luttrell, R. J. Lefkowitz,Nature390, 88–91 (1997)]. Not only these questions lie in the heart of hormone actions and receptor signaling but also dissecting mechanisms underlying these questions could offer therapeutic routes for refractory diseases, such as kidney injury (KI) or X-linked nephrogenic diabetes insipidus (NDI). Here, we identified that Gs-biased signaling, but not Giactivation downstream of EP4, showed beneficial effects for both KI and NDI treatments. Notably, by solving Cryo-electron microscope (cryo-EM) structures of EP3-Gi, EP4-Gs, and EP4-Giin complex with endogenous prostaglandin E2(PGE2)or two synthetic agonists and comparing with PGE2-EP2-Gsstructures, we found that unique primary sequences of prostaglandin E2 receptor (EP) receptors and distinct conformational states of the EP4 ligand pocket govern the Gs/Gitransducer coupling selectivity through different structural propagation paths, especially via TM6 and TM7, to generate selective cytoplasmic structural features. In particular, the orientation of the PGE2ω-chain and two distinct pockets encompassing agonist L902688 of EP4 were differentiated by their Gs/Gicoupling ability. Further, we identified common and distinct features of cytoplasmic side of EP receptors for Gs/Gicoupling and provide a structural basis for selective and biased agonist design of EP4 with therapeutic potential.
- 21 July 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (30)
Open AccessSingle hormone or synthetic agonist induces Gs/Gicoupling selectivity of EP receptors via distinct binding modes and propagating paths
To accomplish concerted physiological reactions, nature has diversified functions of a single hormone at at least two primary levels: 1) Different receptors recognize the same hormone, and 2) different cellular effectors couple to the same hormone–receptor pair [R.P. Xiao,Sci STKE2001, re15 (2001); L. Hein, J. D. Altman, B.K. Kobilka,Nature402, 181–184 (1999); Y. Daaka, L. M. Luttrell, R. J. Lefkowitz,Nature390, 88–91 (1997)]. Not only these questions lie in the heart of hormone actions and receptor signaling but also dissecting mechanisms underlying these questions could offer therapeutic routes for refractory diseases, such as kidney injury (KI) or X-linked nephrogenic diabetes insipidus (NDI). Here, we identified that Gs-biased signaling, but not Giactivation downstream of EP4, showed beneficial effects for both KI and NDI treatments. Notably, by solving Cryo-electron microscope (cryo-EM) structures of EP3-Gi, EP4-Gs, and EP4-Giin complex with endogenous prostaglandin E2(PGE2)or two synthetic agonists and comparing with PGE2-EP2-Gsstructures, we found that unique primary sequences of prostaglandin E2 receptor (EP) receptors and distinct conformational states of the EP4 ligand pocket govern the Gs/Gitransducer coupling selectivity through different structural propagation paths, especially via TM6 and TM7, to generate selective cytoplasmic structural features. In particular, the orientation of the PGE2ω-chain and two distinct pockets encompassing agonist L902688 of EP4 were differentiated by their Gs/Gicoupling ability. Further, we identified common and distinct features of cytoplasmic side of EP receptors for Gs/Gicoupling and provide a structural basis for selective and biased agonist design of EP4 with therapeutic potential.